221 related articles for article (PubMed ID: 37146300)
1. Longitudinal prospective comparison of pancreatic iron by magnetic resonance in thalassemia patients transfusion-dependent since early childhood treated with combination deferiprone-desferrioxamine vs deferiprone or deferasirox monotherapy.
Ricchi P; Meloni A; Pistoia L; Gamberini MR; Cuccia L; Allò M; Putti MC; Spasiano A; Rosso R; Cecinati V; Righi R; Renne S; Peritore G; Vallone A; Positano V; Quaia E; Cademartiri F; Pepe A
Blood Transfus; 2024 Jan; 22(1):75-85. PubMed ID: 37146300
[TBL] [Abstract][Full Text] [Related]
2. Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy.
Pepe A; Meloni A; Rossi G; Cuccia L; D'Ascola GD; Santodirocco M; Cianciulli P; Caruso V; Romeo MA; Filosa A; Pitrolo L; Putti MC; Peluso A; Campisi S; Missere M; Midiri M; Gulino L; Positano V; Lombardi M; Ricchi P
J Cardiovasc Magn Reson; 2013 Jan; 15(1):1. PubMed ID: 23324167
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.
Lin CH; Chen X; Wu CC; Wu KH; Song TS; Weng TF; Hsieh YW; Peng CT
Expert Rev Hematol; 2019 Apr; 12(4):265-272. PubMed ID: 30920854
[TBL] [Abstract][Full Text] [Related]
4. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.
Pepe A; Meloni A; Capra M; Cianciulli P; Prossomariti L; Malaventura C; Putti MC; Lippi A; Romeo MA; Bisconte MG; Filosa A; Caruso V; Quarta A; Pitrolo L; Missere M; Midiri M; Rossi G; Positano V; Lombardi M; Maggio A
Haematologica; 2011 Jan; 96(1):41-7. PubMed ID: 20884710
[TBL] [Abstract][Full Text] [Related]
5. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
Cassinerio E; Orofino N; Roghi A; Duca L; Poggiali E; Fraquelli M; Zanaboni L; Cappellini MD
Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI
Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials.
Xia S; Zhang W; Huang L; Jiang H
PLoS One; 2013; 8(12):e82662. PubMed ID: 24376563
[TBL] [Abstract][Full Text] [Related]
8. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
Fisher SA; Brunskill SJ; Doree C; Gooding S; Chowdhury O; Roberts DJ
Cochrane Database Syst Rev; 2013 Aug; (8):CD004450. PubMed ID: 23963793
[TBL] [Abstract][Full Text] [Related]
9. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
[TBL] [Abstract][Full Text] [Related]
10. Cardiac events and cardiac T2* in Egyptian children and young adults with beta-thalassemia major taking deferoxamine.
Elalfy MS; Abdin IA; El Safy UR; Ibrahim AS; Ebeid FS; Salem DS
Hematol Oncol Stem Cell Ther; 2010; 3(4):174-8. PubMed ID: 21150236
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden.
Voskaridou E; Komninaka V; Karavas A; Terpos E; Akianidis V; Christoulas D
Transfusion; 2014 Mar; 54(3):646-9. PubMed ID: 23834310
[TBL] [Abstract][Full Text] [Related]
12. Deferasirox for managing iron overload in people with thalassaemia.
Bollig C; Schell LK; Rücker G; Allert R; Motschall E; Niemeyer CM; Bassler D; Meerpohl JJ
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD007476. PubMed ID: 28809446
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Deferiprone to Deferasirox and Deferoxamine to Cardiac and Hepatic T2* MRI in Thalassemia Patients: Evidence-based Case Report.
Wahidiyat PA; Yosia M; Sari TT
Acta Med Indones; 2018 Apr; 50(2):168-176. PubMed ID: 29950538
[TBL] [Abstract][Full Text] [Related]
14. MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine.
Pepe A; Meloni A; Pistoia L; Cuccia L; Gamberini MR; Lisi R; D'Ascola DG; Rosso R; Allò M; Spasiano A; Restaino G; Righi R; Mangione M; Positano V; Ricchi P
Br J Haematol; 2018 Dec; 183(5):783-795. PubMed ID: 30334574
[TBL] [Abstract][Full Text] [Related]
15. No difference in myocardial iron concentration and serum ferritin with deferasirox and deferiprone in pediatric patients with hemoglobinopathies: A systematic review and meta-analysis.
Saleem A; Waqar E; Shuja SH; Naeem U; Moeed A; Rais H; Ahmed J
Transfus Clin Biol; 2023 Feb; 30(1):69-74. PubMed ID: 35878782
[TBL] [Abstract][Full Text] [Related]
16. Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: a cost-effectiveness study.
Luangasanatip N; Chaiyakunapruk N; Upakdee N; Wong P
Clin Drug Investig; 2011; 31(7):493-505. PubMed ID: 21627338
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis.
Sridharan K; Sivaramakrishnan G
Expert Rev Clin Pharmacol; 2018 Jun; 11(6):641-650. PubMed ID: 29727586
[TBL] [Abstract][Full Text] [Related]
18. Effects on hearing after long-term use of iron chelators in beta-thalassemia: Over twenty years of longitudinal follow-up.
Aldè M; Ambrosetti U; Giuditta M; Cassinerio E; Piatti G
Auris Nasus Larynx; 2024 Apr; 51(2):271-275. PubMed ID: 37903661
[TBL] [Abstract][Full Text] [Related]
19. How I treat transfusional iron overload.
Hoffbrand AV; Taher A; Cappellini MD
Blood; 2012 Nov; 120(18):3657-69. PubMed ID: 22919029
[TBL] [Abstract][Full Text] [Related]
20. Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit.
Ladis V; Chouliaras G; Berdoukas V; Moraitis P; Zannikos K; Berdoussi E; Kattamis C
Eur J Haematol; 2010 Oct; 85(4):335-44. PubMed ID: 20561034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
